iodine has been researched along with Cough in 13 studies
Iodine: A nonmetallic element of the halogen group that is represented by the atomic symbol I, atomic number 53, and atomic weight of 126.90. It is a nutritionally essential element, especially important in thyroid hormone synthesis. In solution, it has anti-infective properties and is used topically.
diiodine : Molecule comprising two covalently bonded iodine atoms with overall zero charge..
Cough: A sudden, audible expulsion of air from the lungs through a partially closed glottis, preceded by inhalation. It is a protective response that serves to clear the trachea, bronchi, and/or lungs of irritants and secretions, or to prevent aspiration of foreign materials into the lungs.
Excerpt | Relevance | Reference |
---|---|---|
" Chest computed tomography showed the diffuse bronchiectasis in both lungs, and their diagnosis was confirmed by the repeated analysis of a quantitative pilocarpine iontophoresis test (QPIT)." | 7.73 | Cystic fibrosis in Korean children:a case report identified by a quantitative pilocarpine iontophoresis sweat test and genetic analysis. ( Ahn, KM; Kang, IJ; Kim, JH; Lee, JH; Lee, MG; Lee, SI; Park, HY, 2005) |
"The feeding of ethylenediamine dihydriodide (EDDI) at the dose levels of 50 and 500 mg/animal/day and urea at the dose level of 45 g/animal/day did not affect duration of clinical signs, body weight gain, magnitude or duration of fever, serum concentration of glutamic oxalacetic transaminase, packed cell volume, and differential white blood cell counts in feeder cattle experimentally infected with infectious bovine rhinotracheitis (IBR) virus." | 7.65 | Clinical infectious bovine rhinotracheitis in cattle fed organic iodine and urea. ( Brown, LN; Buck, WB; Rosiles, R, 1975) |
" Chest computed tomography showed the diffuse bronchiectasis in both lungs, and their diagnosis was confirmed by the repeated analysis of a quantitative pilocarpine iontophoresis test (QPIT)." | 3.73 | Cystic fibrosis in Korean children:a case report identified by a quantitative pilocarpine iontophoresis sweat test and genetic analysis. ( Ahn, KM; Kang, IJ; Kim, JH; Lee, JH; Lee, MG; Lee, SI; Park, HY, 2005) |
"The feeding of ethylenediamine dihydriodide (EDDI) at the dose levels of 50 and 500 mg/animal/day and urea at the dose level of 45 g/animal/day did not affect duration of clinical signs, body weight gain, magnitude or duration of fever, serum concentration of glutamic oxalacetic transaminase, packed cell volume, and differential white blood cell counts in feeder cattle experimentally infected with infectious bovine rhinotracheitis (IBR) virus." | 3.65 | Clinical infectious bovine rhinotracheitis in cattle fed organic iodine and urea. ( Brown, LN; Buck, WB; Rosiles, R, 1975) |
" Common adverse events in part B included cough (in 19 [56%] of 34 patients) and vomiting (in ten [29%])." | 2.82 | Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study. ( Cooke, J; Cunningham, S; Davies, JC; Green, Y; Harris, WT; Lapey, A; Regelmann, WE; Robertson, S; Rosenfeld, M; Sawicki, GS; Southern, KW, 2016) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 6 (46.15) | 18.7374 |
1990's | 1 (7.69) | 18.2507 |
2000's | 2 (15.38) | 29.6817 |
2010's | 2 (15.38) | 24.3611 |
2020's | 2 (15.38) | 2.80 |
Authors | Studies |
---|---|
Rosiles, R | 1 |
Buck, WB | 1 |
Brown, LN | 1 |
Morgan, EJ | 1 |
Petty, TL | 1 |
Calamai, G | 1 |
Perna, AM | 1 |
Venturini, A | 1 |
Block, SH | 1 |
Kim, M | 1 |
Zang, DY | 1 |
Lee, J | 1 |
Park, JY | 1 |
Chung, Y | 1 |
Lee, YK | 1 |
Berens, DP | 1 |
Huh, HS | 1 |
Mazur, LJ | 1 |
Davies, JC | 1 |
Cunningham, S | 1 |
Harris, WT | 1 |
Lapey, A | 1 |
Regelmann, WE | 1 |
Sawicki, GS | 1 |
Southern, KW | 1 |
Robertson, S | 1 |
Green, Y | 1 |
Cooke, J | 1 |
Rosenfeld, M | 1 |
Claassens, MM | 1 |
van Schalkwyk, C | 1 |
Floyd, S | 1 |
Ayles, H | 1 |
Beyers, N | 1 |
Lukela, M | 1 |
DeGuzman, D | 1 |
Weinberger, S | 1 |
Saint, S | 1 |
Ahn, KM | 1 |
Park, HY | 1 |
Lee, JH | 1 |
Lee, MG | 1 |
Kim, JH | 1 |
Kang, IJ | 1 |
Lee, SI | 1 |
Wood, RE | 1 |
McCombs, ML | 1 |
Shwachman, H | 1 |
Redmond, A | 1 |
Khaw, KT | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Phase 3, 2-Part, Open-Label Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are 2 Through 5 Years of Age and Have a CFTR Gating Mutation[NCT01705145] | Phase 3 | 35 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
BMI = (Weight [in kg]) divided by (Stature [in meters])^2. Data was reported as per the dose received and for overall participants. (NCT01705145)
Timeframe: Baseline, Week 24
Intervention | kilogram per square meter (kg/m^2) (Mean) |
---|---|
Part B: Ivacaftor 50 mg | 0.332 |
Part B: Ivacaftor 75 mg | 0.314 |
Part B: Overall Ivacaftor | 0.319 |
Stature was measured as height if children could stand unassisted and follow directions; otherwise, stature was measured as length. Data was reported as per the dose received and for overall participants. (NCT01705145)
Timeframe: Part B: Baseline, Week 24
Intervention | centimeters (cm) (Mean) |
---|---|
Part B: Ivacaftor 50 mg | 2.5 |
Part B: Ivacaftor 75 mg | 3.5 |
Part B: Overall Ivacaftor | 3.3 |
Sweat samples were collected using an approved Macroduct (Wescor, Logan, Utah) collection device. A volume of greater than or equal to (>=) 15 microliter was required for determination of sweat chloride. Data was reported as per the dose received and for overall participants. (NCT01705145)
Timeframe: Part B: Baseline, Week 24
Intervention | millimole per liter (mmol/L) (Mean) |
---|---|
Part B: Ivacaftor 50 mg | -47.07 |
Part B: Ivacaftor 75 mg | -46.78 |
Part B: Overall Ivacaftor | -46.86 |
Data was reported as per the dose received and for overall participants. (NCT01705145)
Timeframe: Part B: Baseline, Week 24
Intervention | kilograms (kg) (Mean) |
---|---|
Part B: Ivacaftor 50 mg | 1.00 |
Part B: Ivacaftor 75 mg | 1.50 |
Part B: Overall Ivacaftor | 1.36 |
"AE: any adverse change from participant's baseline (pre-treatment) condition, including any adverse experience, abnormal recording/clinical laboratory assessment which occurs during course of study, whether it is considered related to study drug or not. SAE: medical event or condition, which falls into any of following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, in-patient hospitalization/prolonged hospitalization, persistent/significant disability/incapacity, congenital anomaly/birth defect, important medical event.~Related AEs includes all AEs for which the causality was either related to study drug or possibly related to study drug. Data was reported as per the dose received and for overall participants." (NCT01705145)
Timeframe: Part A: Up to 93 Days
Intervention | participants (Number) | ||
---|---|---|---|
AEs | SAEs | Related AEs | |
Part A: Ivacaftor 50 mg | 3 | 0 | 1 |
Part A: Ivacaftor 75 mg | 5 | 0 | 3 |
Part A: Overall Ivacaftor | 8 | 0 | 4 |
Plasma concentration was reported for ivacaftor and its metabolites (hydroxymethyl ivacaftor [M1] and ivacaftor carboxylate [M6]) up to 24 hours post-dose on Day 4 (Hour 0 [pre-dose] on Day 1 and Day 4; 2, 3, 6, 24 hours post-dose on Day 4). Data was planned to be reported for overall participants in the period. (NCT01705145)
Timeframe: Part A: up to 24 hours post-dose on Day 4
Intervention | nanogram per milliliter (ng/mL) (Mean) | |||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ivacaftor: Hour 0 on Day 1 | Ivacaftor: Hour 0 on Day 4 | Ivacaftor: 2 Hours Post-Dose on Day 4 | Ivacaftor: 3 Hours Post-Dose on Day 4 | Ivacaftor: 6 Hours Post-Dose on Day 4 | Ivacaftor: 24 Hours Post-Dose on Day 4 | M1: Hour 0 on Day 1 | M1: Hour 0 on Day 4 | M1: 2 Hours Post-Dose on Day 4 | M1: 3 Hours Post-Dose on Day 4 | M1: 6 Hours Post-Dose on Day 4 | M1: 24 Hours Post-Dose on Day 4 | M6: Hour 0 on Day 1 | M6: Hour 0 on Day 4 | M6: 2 Hours Post-Dose on Day 4 | M6: 3 Hours Post-Dose on Day 4 | M6: 6 Hours Post-Dose on Day 4 | M6: 24 Hours Post-Dose on Day 4 | |
Part A: Overall Ivacaftor | 0.00 | 396 | 726 | 957 | 542 | 124 | 0.00 | 1240 | 1540 | 2310 | 1580 | 389 | 0.00 | 1150 | 1050 | 1300 | 1390 | 439 |
"AE: any adverse change from participant's baseline (pre-treatment) condition, including any adverse experience, abnormal recording/clinical laboratory assessment which occurs during course of study, whether it is considered related to study drug or not. AE includes both serious and non-serious AE. SAE: medical event or condition, which falls into any of following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, in-patient hospitalization/prolonged hospitalization, persistent/significant disability/incapacity, congenital anomaly/birth defect, important medical event.~Related AEs includes all AEs for which the causality was either related to study drug or possibly related to study drug. Data was reported as per the dose received." (NCT01705145)
Timeframe: Part B: Up to 28 Weeks
Intervention | participants (Number) | ||
---|---|---|---|
AEs | SAEs | Related AEs | |
Part B: Ivacaftor 50 mg | 10 | 3 | 3 |
Part B: Ivacaftor 75 mg | 23 | 3 | 8 |
Part B: Overall Ivacaftor | 33 | 6 | 11 |
Plasma concentration was reported for ivacaftor and its metabolites (M1 and M6) up to 24 hours post-dose on Day 168 (Hour 0 [predose] on Day 1, 14, 56, 112, and 168; 2, 3, 6 hours post-dose on Day 14; 1 hour post-dose on Day 56; 4, 6 hours post-dose on Day 112; 24 hours post-dose on Day 168). Data was planned to be reported for overall participants in the period. (NCT01705145)
Timeframe: Part B: up to 24 hours post-dose on Day 168
Intervention | ng/mL (Mean) | |||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ivacaftor: Hour 0 on Day 1 | Ivacaftor: Hour 0 on Day 14 | Ivacaftor: 2 Hours Post-Dose on Day 14 | Ivacaftor: 3 Hours Post-Dose on Day 14 | Ivacaftor: 6 Hours Post-Dose on Day 14 | Ivacaftor: Hour 0 on Day 56 | Ivacaftor: 1 Hour Post-Dose on Day 56 | Ivacaftor: Hour 0 on Day 112 | Ivacaftor: 4 Hours Post-Dose on Day 112 | Ivacaftor: 6 Hours Post-Dose on Day 112 | Ivacaftor: Hour 0 on Day 168 | Ivacaftor: 24 Hours Post-Dose on Day 168 | M1: Hour 0 on Day 1 | M1: Hour 0 on Day 14 | M1: 2 Hours Post-Dose on Day 14 | M1: 3 Hours Post-Dose on Day 14 | M1: 6 Hours Post-Dose on Day 14 | M1: Hour 0 on Day 56 | M1: 1 Hour Post-Dose on Day 56 | M1: Hour 0 on Day 112 | M1: 4 Hours Post-Dose on Day 112 | M1: 6 Hours Post-Dose on Day 112 | M1: Hour 0 on Day 168 | M1: 24 Hours Post-Dose on Day 168 | M6: Hour 0 on Day 1 | M6: Hour 0 on Day 14 | M6: 2 Hours Post-Dose on Day 14 | M6: 3 Hours Post-Dose on Day 14 | M6: 6 Hours Post-Dose on Day 14 | M6: Hour 0 on Day 56 | M6: 1 Hour Post-Dose on Day 56 | M6: Hour 0 on Day 112 | M6: 4 Hours Post-Dose on Day 112 | M6: 6 Hours Post-Dose on Day 112 | M6: Hour 0 on Day 168 | M6: 24 Hours Post-Dose on Day 168 | |
Part B: Overall Ivacaftor | 0.00 | 614 | 932 | 1080 | 1140 | 448 | 514 | 596 | 1080 | 1010 | 500 | 207 | 0.00 | 1580 | 1870 | 2280 | 2670 | 1340 | 1170 | 1680 | 2450 | 2500 | 1460 | 602 | 0.00 | 1520 | 1430 | 1630 | 2090 | 1510 | 1310 | 1660 | 1810 | 2130 | 1520 | 632 |
3 reviews available for iodine and Cough
Article | Year |
---|---|
Hydatid disease of the heart. Report of five cases and review of the literature.
Topics: Adolescent; Adult; Cardiomegaly; Child; Cough; Diagnosis, Differential; Echinococcosis; Edema; Elect | 1974 |
Cystic fibrosis: diagnosis, treatment, and prognosis.
Topics: Aerosols; Anti-Bacterial Agents; Cough; Cystic Fibrosis; Diet; Female; Humans; Infant, Newborn; Infa | 1979 |
Research in cystic fibrosis: a review.
Topics: Biological Transport; Calcium; Cells, Cultured; Child; Chlorides; Cough; Cystic Fibrosis; Digestive | 1973 |
2 trials available for iodine and Cough
Article | Year |
---|---|
Summary of the National Mucolytic Study.
Topics: Aged; Bronchitis; Chest Pain; Consumer Behavior; Cough; Double-Blind Method; Expectorants; Female; G | 1990 |
Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study.
Topics: Aminophenols; Child, Preschool; Chloride Channel Agonists; Chlorides; Cough; Cystic Fibrosis; Cystic | 2016 |
8 other studies available for iodine and Cough
Article | Year |
---|---|
Clinical infectious bovine rhinotracheitis in cattle fed organic iodine and urea.
Topics: Ammonia; Animals; Cattle; Cattle Diseases; Cough; Female; Fibrinogen; Infectious Bovine Rhinotrachei | 1975 |
Goiter complicating therapy with iodinated glycerol (Organidin).
Topics: Adolescent; Cough; Expectorants; Female; Follow-Up Studies; Glycerol; Goiter; Humans; Iodine; Thyroi | 1973 |
Mixed Phenotype Acute Leukemia that Evolved from Myelodysplastic Syndrome with Excess Blasts.
Topics: Aged; B-Lymphocytes; Basophils; Carcinogenesis; Cough; Dyspnea; Female; Humans; Korea; Leukemia, Bip | 2020 |
Weight Loss, Fever, Cough, and Night Sweats in an 11-year-old Girl.
Topics: Child; Cough; Diagnosis, Differential; Female; Fever; Humans; Sweat; Weight Loss | 2020 |
Symptom screening rules to identify active pulmonary tuberculosis: Findings from the Zambian South African Tuberculosis and HIV/AIDS Reduction (ZAMSTAR) trial prevalence surveys.
Topics: Black People; Communicable Diseases; Cough; Dyspnea; Female; Fever; HIV Infections; Humans; Male; Ma | 2017 |
Clinical problem-solving. Unfashionably late.
Topics: Adolescent; Biopsy; Burkholderia cepacia; Burkholderia Infections; Chest Pain; Chlorides; Cough; Cys | 2005 |
Cystic fibrosis in Korean children:a case report identified by a quantitative pilocarpine iontophoresis sweat test and genetic analysis.
Topics: Blood Pressure; Bronchiectasis; Child; Cough; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conduct | 2005 |
Studies in cystic fibrosis. Report of 130 patients diagnosed under 3 months of age over a 20-year period.
Topics: Anemia; Body Weight; Chloramphenicol; Chlortetracycline; Cough; Cystic Fibrosis; Diabetes Mellitus, | 1970 |